Large epidemiological studies of human populations have shown that significantly enhanced levels of FGF21 accompany obesity, impaired glucose tolerance, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) [2], [6], [7]. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.